⌘K

Login Start Free

Home/Filings/4/0001209191-23-002417

4//SEC Filing

Lebwohl David 4

Accession 0001209191-23-002417

CIK 0001652130other

View on SEC.gov Company Profile

Filed

Jan 5, 7:00 PM ET

Accepted

Jan 6, 5:26 PM ET

Size

4.8 KB

Accession

0001209191-23-002417

Insider Transaction Report

Form 4

Period: 2023-01-04

Intellia Therapeutics, Inc.NTLA

EVP, Chief Medical Officer

Transactions

Sale
Common Stock
2023-01-04$37.21/sh−2,574$95,779→ 25,687 total

Footnotes (1)

[F1]Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1

filerCIK 0001810882

Filing Metadata

Form type: 4
Filed: Jan 5, 7:00 PM ET
Accepted: Jan 6, 5:26 PM ET
Size: 4.8 KB

View on SEC.gov